Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02386527 · ClinicalTrials.gov registry record
Consortium of Early Arthritis Cohorts USA
A clinical trial, sponsored by Hospital for Special Surgery, New York.
- Terminated
- Registry status
- 119
- Enrollment target
NCT02386527: Clinical Trial study, sponsored by Hospital for Special Surgery, New York.
NCT02386527 is a clinical trial that was terminated before completion, run by Hospital for Special Surgery, New York. The registered enrollment target is 119 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02386527 was terminated before completion, sponsored by Hospital for Special Surgery, New York.
- TERMINATED
- Registry status
- 119 participants
- Enrollment target
Study Summary
Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis. In the US, it is estimated that as many as 3 million adults may suffer from the disease. Fortunately in the last few years, a shift in strategy toward the earlier institution of disease modifying drugs and the availability of new classes of medications have greatly improved the outcomes that can be expected by most patients. The goal of treatment now aims toward achieving the lowest possible level of arthritis disease activity and even remission, if possible as early on as possible. Research has shown that this translates into minimized joint damage and enhanced physical function and quality of life for the RA patient. This also requires that a diagnosis of RA be made as early on as possible, and herein lies the challenge, i.e. identifying the RA patient early on in the course of their disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2014-12-01 |
| Est. Completion | 2024-04 |
Why NCT02386527 stopped before completion
NCT02386527 is an observational study that tracks outcomes without assigning an intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02386527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02386527 about?
NCT02386527 is a clinical study titled "Consortium of Early Arthritis Cohorts USA". Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis. In the US, it is estimated that as many as 3 million adults may suffer from the disease. Fortunately in the last few years, a shift in strategy toward the earlier institution of disease modifying drugs and the availability ...
What is the current status of trial NCT02386527?
This trial is currently terminated. The enrollment target is 119 participants. The study started on 2014-12-01. Estimated completion is 2024-04.
Who is sponsoring clinical trial NCT02386527?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI